KRAS, a New Target for Precision Medicine in Colorectal Cancer?
Alice Boilève1,2,3, Cristina Smolenschi1,4, Aurélien Lambert5
1Gustave Roussy, Département de Médecine Oncologique, 94805 Villejuif, France.
Cancers
|October 26, 2024
Summary
Targeting KRAS mutations in colorectal cancer (CRC) is advancing. New KRAS inhibitors show promise for improving outcomes in CRC patients, despite challenges like resistance.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Colorectal cancer (CRC) is a major global health concern, with KRAS mutations often linked to poor prognosis.
- KRAS oncogene has historically been challenging to target therapeutically due to its complex structure.
Purpose of the Study:
- To review recent advancements in KRAS inhibition strategies for colorectal cancer.
- To explore the efficacy and challenges of emerging KRAS inhibitors and combination therapies.
Main Methods:
- Literature review of recent studies and clinical trials on KRAS inhibitors in CRC.
- Analysis of different classes of KRAS inhibitors (covalent, non-covalent) and combination approaches.
Main Results:
- Emergence of KRAS inhibitors as viable therapeutic options for CRC.
- Clinical trials demonstrate potential efficacy of KRAS inhibitors, alone or with other agents like anti-EGFR antibodies.
Conclusions:
- KRAS inhibitors represent a significant therapeutic advance in colorectal cancer treatment.
- Ongoing research aims to overcome resistance mechanisms and tumor heterogeneity for improved patient outcomes.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K